Table 1.
Participant characteristics by study group.
| Treatment Group | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| All | mDOT | GT | SIT | ||||||
| Characteristic | N | % | N | % | N | % | N | % | p-value |
| Total | 61 | 100 | 13 | 21 | 15 | 25 | 33 | 54 | |
| Age | |||||||||
| (Mean, SD) | 53 | 9 (SD) | 55 | 8 (SD) | 53 | 11 (SD) | 52 | 9 (SD) | 0.74 |
| Gender | |||||||||
| Male | 38 | 62% | 6 | 46% | 9 | 60% | 23 | 70% | 0.34 |
| Hispanic Ethnicity | |||||||||
| Yes | 41 | 67% | 9 | 69% | 8 | 53% | 24 | 73% | 0.41 |
| Cirrhosis | |||||||||
| Yes | 20 | 33% | 3 | 23% | 7 | 47% | 10 | 30% | 0.39 |
| HIV | |||||||||
| Yes | 14 | 23% | 7 | 54% | 1 | 7% | 6 | 18% | 0.01 |
| Depression | |||||||||
| Yes | 38 | 62% | 10 | 77% | 12 | 80% | 16 | 49% | 0.05 |
| Genotype | |||||||||
| 1 | 59 | 97% | 13 | 100% | 14 | 93% | 32 | 97% | 0.61 |
| HCV Treatment Experience | |||||||||
| Yes | 12 | 20% | 1 | 8% | 5 | 33% | 6 | 18% | 0.22 |
| Treatment Medication | |||||||||
| Sofosbuvir/Ledipasvir&&&90 mg/400mg | 46 | 75% | 12 | 92% | 6 | 40% | 28 | 85% | 0.001 |
| Simeprevir150mg/ Sofosbuvir400mg | 15 | 27% | 1 | 8% | 9 | 60% | 5 | 15% | 0.001 |
| Benzodiazepine Use 6 M Prior to HCV Treatment | |||||||||
| Yes | 18/58 | 31% | 5/13 | 39% | 5/14 | 36% | 8/31 | 26% | 0.60 |
| Benzodiazepine Use During HCV Treatment | |||||||||
| Yes | 14/68 | 24% | 5/13 | 39% | 3/14 | 21% | 6/31 | 19% | 0.42 |
| Cocaine Use 6 M Prior to HCV Treatment | |||||||||
| Yes | 20/58 | 34% | 7/13 | 54% | 7/14 | 50% | 6/31 | 19% | 0.03 |
| Cocaine Use During HCV Treatment | |||||||||
| Yes | 13/58 | 22% | 5/13 | 39% | 4/10 | 29% | 4/31 | 13% | 0.13 |
| Opioid Use 6 M Prior to HCV Treatment | |||||||||
| Yes | 24/58 | 41% | 9/13 | 69% | 6/14 | 43% | 9/31 | 29% | 0.05 |
| Opioid Use During HCV Treatment | |||||||||
| Yes | 23/58 | 40% | 7/13 | 54% | 5/14 | 36% | 11/31 | 36% | 0.50 |
| Any Drug Use 6 M Prior to HCV Treatment | |||||||||
| Yes | 35/58 | 60% | 10/13 | 77% | 11/14 | 79% | 14/31 | 45% | 0.040 |
| Any Drug Use During HCV Treatment | |||||||||
| Yes | 34/58 | 59% | 9/13 | 69% | 10/14 | 71.4% | 15/31 | 48% | 0.24 |
| Frequent Drug Use 6 M Prior to HCV Treatment | |||||||||
| Yes | 13/58 | 22% | 4/13 | 21% | 3/14 | 21% | 6/31 | 19% | 0.65 |
| Frequent Drug Use During HCV Treatment | |||||||||
| Yes | 13/58 | 22% | 5/13 | 38% | 4/10 | 29% | 4/31 | 13% | 0.13 |
Abbreviations : mDOT (modified directly observed therapy); GT (group treatment); SIT (self-administered individual treatment); M (month).